Clinical Trials Logo

Muscle Weakness clinical trials

View clinical trials related to Muscle Weakness.

Filter by:
  • No longer available  
  • Page 1

NCT ID: NCT02012933 No longer available - Clinical trials for Lambert-Eaton Myasthenic Syndrome (LEMS)

3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)

Start date: n/a
Phase:
Study type: Expanded Access

Lambert-Eaton Myasthenic Syndrome (LEMS) is a rare autoimmune disorder which affects the nerve-muscle junction. The major symptoms of LEMS are progressive muscle weakness. Many patients experience other symptoms like dry mouth or impotence. Congenital Myasthenia (CM) is an inherited disorder with similar affects and symptoms. 3,4-Diaminopyridine (DAP) is an experimental drug that has improved strength in some subjects with (LEMS). There are no other accepted treatments for LEMS and DAP has relatively few side effects.